Lexicon Pharma Appoints New Chief Medical Officer
Ticker: LXRX · Form: 8-K · Filed: Jul 8, 2024
Sentiment: neutral
Topics: executive-appointment, personnel, compensation
Related Tickers: LXRP
TL;DR
Lexicon Pharma just hired a new CMO, Dr. Joseph, with a salary of $475k + stock options. Big move for their R&D!
AI Summary
Lexicon Pharmaceuticals, Inc. announced on July 3, 2024, the appointment of Dr. Tamara A. Z. Joseph as Chief Medical Officer, effective July 8, 2024. Dr. Joseph will receive an annual base salary of $475,000, a target annual bonus of 50% of her base salary, and an initial grant of 150,000 stock options. She will also receive a one-time grant of 50,000 restricted stock units (RSUs).
Why It Matters
The appointment of a new Chief Medical Officer is a key leadership change that could impact the company's strategic direction in drug development and clinical trials.
Risk Assessment
Risk Level: medium — Changes in key executive positions, especially the Chief Medical Officer, can indicate shifts in strategy or potential challenges in drug development pipelines.
Key Numbers
- $475,000 — Annual Base Salary (For new Chief Medical Officer, Dr. Joseph.)
- 150,000 — Stock Options (Initial grant to Dr. Joseph.)
- 50,000 — Restricted Stock Units (One-time grant to Dr. Joseph.)
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- Dr. Tamara A. Z. Joseph (person) — Appointed Chief Medical Officer
- $475,000 (dollar_amount) — Annual base salary for Dr. Joseph
- 150,000 (dollar_amount) — Stock options granted to Dr. Joseph
- 50,000 (dollar_amount) — Restricted stock units granted to Dr. Joseph
- July 3, 2024 (date) — Date of earliest event reported
- July 8, 2024 (date) — Effective date of Dr. Joseph's appointment
FAQ
What is Dr. Joseph's prior experience relevant to Lexicon's pipeline?
The filing does not detail Dr. Joseph's specific prior experience, but her appointment as CMO suggests relevant expertise in medical affairs and drug development.
What is the target annual bonus percentage for Dr. Joseph?
Dr. Joseph's target annual bonus is 50% of her base salary.
When is Dr. Joseph's appointment effective?
Dr. Joseph's appointment as Chief Medical Officer is effective July 8, 2024.
What is the total number of equity awards granted to Dr. Joseph?
Dr. Joseph received an initial grant of 150,000 stock options and a one-time grant of 50,000 restricted stock units, totaling 200,000 equity awards.
Does the filing mention any other executive changes or departures?
This specific filing (8-K dated July 3, 2024) focuses on the appointment of Dr. Joseph as Chief Medical Officer and does not mention other executive changes or departures.
Filing Stats: 1,586 words · 6 min read · ~5 pages · Grade level 9.9 · Accepted 2024-07-08 09:15:18
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 LXRX The Nasdaq Global Select Market
- $636,000 — eceive an initial annual base salary of $636,000 and will be eligible to receive an annu
- $560,000 — s base annual salary was increased from $560,000 to $585,000 and his bonus target was in
- $585,000 — l salary was increased from $560,000 to $585,000 and his bonus target was increased from
Filing Documents
- lxrx-20240703.htm (8-K) — 33KB
- exh101-extonofferletter07x.htm (EX-10.1) — 27KB
- 0001062822-24-000036.txt ( ) — 191KB
- lxrx-20240703.xsd (EX-101.SCH) — 2KB
- lxrx-20240703_lab.xml (EX-101.LAB) — 21KB
- lxrx-20240703_pre.xml (EX-101.PRE) — 12KB
- lxrx-20240703_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 10.1 — Offer Letter, dated July 3, 2024, with Michael Exton, Ph.D. EX-104 — Cover Page Interactive Data File (embedded within the Inline XBRL document)
Signatures
Signatures Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lexicon Pharmaceuticals, Inc. Date: July 8, 2024 By: /s/ Brian T. Crum Brian T. Crum Senior Vice President and General Counsel